European Medicines Agency grants brensocatib Priority Medicines (PRIME) designation for the treatment of non-cystic fibrosis bronchiectasis (NCFBE)

Brensocatib is a first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 being developed for treatment of NCFBE and other inflammatory diseases. The designation is based on positive results from the randomised, double-blind, placebo-controlled Phase 2 WILLOW study.

Source:

Biospace Inc.